$4.09
0.99% day before yesterday
Nasdaq, Nov 07, 10:20 pm CET
ISIN
US7995661045
Symbol
SANA

Sana Biotechnology Inc Stock price

$4.09
-0.03 0.73% 1M
+2.39 140.59% 6M
+2.46 150.92% YTD
+0.99 31.94% 1Y
-0.47 10.31% 3Y
-31.01 88.35% 5Y
-31.01 88.35% 10Y
-31.01 88.35% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
+0.04 0.99%
ISIN
US7995661045
Symbol
SANA
Industry

New AI Insights on Sana Biotechnology Inc Insights AI Insights on Sana Biotechnology Inc

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$985.4m
Net debt
positive
Cash
$72.7m
Shares outstanding
230.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
8.6
Financial Health
Equity Ratio
50.0%
Return on Equity
-106.5%
ROCE
-64.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-196.4m | $-221.6m
EBIT
$-212.6m | $-216.1m
Net Income
$-252.2m | $-205.9m
Free Cash Flow
$-185.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
12.9% | 13.2%
EBIT
14.6% | 20.8%
Net Income
-3.0% | 22.8%
Free Cash Flow
35.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.1
FCF per Share
$-0.8
Short interest
34.6%
Employees
194
Rev per Employee
$0.0
Show more

Is Sana Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Sana Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Sana Biotechnology Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Sana Biotechnology Inc forecast:

Buy
87%
Hold
13%

Financial data from Sana Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 53 53
27% 27%
-
- Research and Development Expense 167 167
32% 32%
-
-196 -196
13% 13%
-
- Depreciation and Amortization 16 16
31% 31%
-
EBIT (Operating Income) EBIT -213 -213
15% 15%
-
Net Profit -252 -252
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Sana Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sana Biotechnology Inc Stock News

Positive
Seeking Alpha
23 days ago
Sana Biotechnology, Inc. remains a Strong Buy, driven by progress in HIP-modified cell therapies for Type 1 Diabetes and B-cell-mediated disorders. Sana Biotechnology's HIP-modified islet cell therapy showed a 6-month insulin response without needing immunosuppression in one T1D patient, supporting a paradigm shift in treatment. Upcoming 2025 data readouts from phase 1 GLEAM (SC291, autoimmune ...
Positive
Seeking Alpha
23 days ago
Sana Biotechnology, Inc. surged after hedge fund manager Eric Jackson called it a potential "100-bagger" due to its pioneering diabetes cell therapy. Sana Biotechnology's breakthrough islet cell therapy, using proprietary hypoimmune technology, enabled insulin production in a type 1 diabetes patient without immunosuppression. Significant challenges remain: scalable cell manufacturing, safe and ...
Neutral
Seeking Alpha
2 months ago
Sana Biotechnology, Inc. (NASDAQ:SANA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Well, hello, everyone. I'm Maxwell Skor, biotech analyst with Morgan Stanley.
More Sana Biotechnology Inc News

Company Profile

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses in identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 13, 2018 and is headquartered in Seattle, WA.

Head office United States
CEO Steven Harr
Employees 194
Founded 2018
Website sana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today